Russian Sputnik V coronavirus vaccine 91.6% effective in interim analysis

Published



The Russian Sputnik V COVID-19 vaccine is 91.6% effective, according to an interim analysis of a late-stage, phase 3 clinical trial.

Published on Tuesday by the British medical journal Lancet, the analysis found the Sputnik V vaccine is safe and effective, with no reports of serious adverse side effects.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.